With 2021 biopharma financings already at 40% of last year’s total, there is a good likelihood that a new record will be made for the industry, assuming wide open public windows and robust venture capital activity continue.
The rocky first quarter for public biopharmaceutical companies continued into April as the BioWorld Biopharmaceutical index remained flat for the period in contrast to the general market, with the Dow Jones Industrial Average growing by more than 2%. Weighing on the sector has been softer than expected earnings in the period among the top tier companies.
Dangerous blood clots and thrombocytopenia, rare simultaneous side effects seen with two adenoviral vector vaccines from Astrazeneca plc and Johnson & Johnson, as well as a worldwide spike in COVID-19 cases and deaths, primarily in India, has set the stage for what could soon become the next big vaccine option, a protein subunit candidate from Gaithersburg, Md.-based Novavax Inc.
RSS
